Academic Journal

Comparing the Effectiveness of Afatinib and Osimertinib for Patients With PD-L1-positive EGFR-mutant Non-small Cell Carcinoma.

التفاصيل البيبلوغرافية
العنوان: Comparing the Effectiveness of Afatinib and Osimertinib for Patients With PD-L1-positive EGFR-mutant Non-small Cell Carcinoma.
المؤلفون: MINEHIKO INOMATA, YOSUKE KAWASHIMA, RYOTA SAITO, DAISUKE MORINAGA, HITOMI NOGAWA, MASAMICHI SATO, YOHEI SUZUKI, SATORU YANAGISAWA, TAKASHI KIKUCHI, DAISUKE JINGU, NARUO YOSHIMURA, TOSHIYUKI HARADA, EISAKU MIYAUCHI
المصدر: Cancer Diagnosis & Prognosis; Jul/Aug2024, Vol. 4 Issue 4, p515-520, 6p
مصطلحات موضوعية: OSIMERTINIB, AFATINIB, EPIDERMAL growth factor, NON-small-cell lung carcinoma, KINASE inhibitors
مستخلص: Background/Aim: Epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) are effective for treating non-small cell lung cancer (NSCLC) harboring EGFR mutations. However, higher tumor programmed death ligand-1 (PD-L1) expression is associated with a poor response to EGFR-TKIs, and information on the comparison between afatinib and osimertinib in PD-L1-positive EGFR-mutant NSCLC is scarce. Patients and Methods: We retrospectively analyzed data of patients with PD-L1-positive EGFR-mutant NSCLC to compare the effectiveness of afatinib and osimertinib. Results: A total of 177 patients were included in the study. The Cox proportion hazard model was adjusted for age, sex, performance status, EGFR mutation status, PD-L1 expression level, and brain metastasis, revealing that there was no significant difference in risk for progression [hazard ratio (HR)=0.99, 95% confidence interval (CI)=0.64-1.53] or death (HR=0.96, 95% CI=0.54-1.73) between afatinib and osimertinib. Conclusion: In conclusion, the EGFR-TKI treatment duration and overall survival after the treatment with afatinib or osimertinib were similar in patients with PD-L1- positive EGFR-mutant NSCLC in the present study. [ABSTRACT FROM AUTHOR]
Copyright of Cancer Diagnosis & Prognosis is the property of International Institute of Anticancer Research and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:27327787
DOI:10.21873/cdp.10357